Healthcare of Ontario Pension Plan Trust Fund Acquires 47,676 Shares of West Pharmaceutical Services, Inc. $WST

Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 1,676.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,520 shares of the medical instruments supplier’s stock after buying an additional 47,676 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in West Pharmaceutical Services were worth $12,662,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Elyxium Wealth LLC acquired a new stake in shares of West Pharmaceutical Services in the fourth quarter worth about $25,000. CYBER HORNET ETFs LLC acquired a new position in shares of West Pharmaceutical Services during the 2nd quarter valued at about $25,000. Cornerstone Planning Group LLC increased its holdings in shares of West Pharmaceutical Services by 90.9% during the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 50 shares during the last quarter. Bayban bought a new position in shares of West Pharmaceutical Services in the 4th quarter valued at approximately $27,000. Finally, Private Trust Co. NA raised its stake in shares of West Pharmaceutical Services by 156.4% in the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 61 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors.

West Pharmaceutical Services Price Performance

Shares of NYSE:WST opened at $331.52 on Tuesday. The company has a market cap of $23.33 billion, a price-to-earnings ratio of 42.45, a PEG ratio of 2.56 and a beta of 1.16. The business has a 50 day moving average price of $337.57 and a 200 day moving average price of $287.85. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a twelve month low of $223.83 and a twelve month high of $386.00.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The company had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. During the same period in the previous year, the business posted $1.84 EPS. The company’s revenue for the quarter was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Research analysts predict that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th will be given a dividend of $0.22 per share. The ex-dividend date of this dividend is Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. West Pharmaceutical Services’s payout ratio is 11.27%.

Wall Street Analysts Forecast Growth

WST has been the subject of a number of recent analyst reports. Evercore reaffirmed an “outperform” rating and set a $425.00 target price on shares of West Pharmaceutical Services in a research report on Monday. Citigroup reissued a “buy” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Wolfe Research initiated coverage on shares of West Pharmaceutical Services in a research note on Monday, June 1st. They issued an “outperform” rating and a $375.00 price objective for the company. KeyCorp upped their price objective on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. Finally, BNP Paribas Exane began coverage on shares of West Pharmaceutical Services in a research note on Monday, July 13th. They issued an “outperform” rating and a $447.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, West Pharmaceutical Services currently has an average rating of “Buy” and an average price target of $364.42.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.